ArticleMolecular biology reports2025
Immune profiling of kidney transplant recipients: the role of Tribbles-1, Perforin, and Granzyme B in chronic humoral rejection.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFor patients with end-stage renal disease (ESRD), kidney transplantation is the most effective treatment option, yet chronic antibody-mediated rejection (cAMR) remains a key challenge to long-term graft survival. Natural killer (NK) cells are implicated in allograft rejection, but their precise role remains unclear. This study assessed NK cell activity and the expression of Tribbles-1, Perforin, and Granzyme B in kidney transplant recipients with either stable grafts or cAMR.
methodsPeripheral blood samples from 60 transplant recipients (30 stable grafts, 30 cAMR) were analyzed for NK cell percentages, activation (CD107a expression), and gene expression of Perforin, Granzyme B, and Tribbles-1 using real-time PCR.
resultsNK cell numbers were similar in both groups, likely due to the influence of immunosuppressive therapy. However, cAMR patients exhibited significantly higher CD107a expression, suggesting heightened NK cell activation, potentially due to suboptimal immunosuppressive dosing. While Perforin and Tribbles-1 expression showed no significant differences between the two groups, Granzyme B expression was higher in stable graft recipients than in those with cAMR.
conclusionThese findings indicate that peripheral blood Granzyme B expression is not a specific biomarker for graft dysfunction, as elevated levels were also observed in stable graft recipients. Additionally, since Granzyme B is expressed in multiple immune cell types, its elevated levels in stable patients may indicate broader immune activation rather than graft dysfunction. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
40488991What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.